Facebook Follow AMS on Linkedin Follow us on Twitter @amsmenopausen AMS on Instagram

Adjuvant hormone therapy in ovarian cancer

Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial

To assess the effects of adjuvant hormone therapy (AHT) on survival and disease outcome in women with epithelial ovarian cancer.

Participants were premenopausal and postmenopausal women who had been diagnosed with epithelial ovarian cancer (any International Federation of Gynecology and Obstetrics stage) 9 or fewer months previously. Ineligible patients included those with deliberately preserved ovarian function, with a history of a hormone-dependent malignancy, or with any contraindications to hormone-replacement therapy. Patients were centrally randomly assigned in a 1:1 ratio to either AHT for 5 years after random assignment or no AHT (control). Main outcome measures were overall survival (OS), defined as time from random assignment to death (any cause), and relapse-free survival, defined as time from random assignment to relapse or death (any cause). Patients who continued, alive and relapse free, were censored at their last known follow-up.

A total of 150 patients (n = 75, AHT; n = 75, control) were randomly assigned from 1990 to 1995 from 19 centers in the United Kingdom, Spain, and Hungary; all patients were included in intention-to-treat analyses. The median follow-up in alive patients is currently 19.1 years. Of the 75 patients with AHT, 53 (71%) have died compared with 68 (91%) of 75 patients in the control group. OS was significantly improved in patients who were receiving AHT (hazard ratio, 0.63; 95% CI, 0.44 to 0.90; P = .011). A similar effect was seen for relapse-free survival (hazard ratio, 0.67; 95% CI, 0.47 to 0.97; P = .032). Effects remained after adjustment for known prognostic factors.

These results show that women who have severe menopausal symptoms after ovarian cancer treatment can safely take hormone-replacement therapy, and this may, in fact, infer benefits in terms of OS in addition to known advantages in terms of quality of life.


Eeles RA, Morden JP, Gore M, et al. (2015) Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: Results of the adjuvant hormone therapy randomized trial. J Clin Oncol 33:4138–4144


Where do we stand in 2015? To treat or not to treat? Although there are many unanswered questions (eg, the mechanisms of how estrogen improves overall survival, the optimal duration of therapy), the data from Eeles et al16 combined with that of previous studies allow oncologists to feel comfortable offering patients HRT after the treatment of epithelial ovarian cancer to reduce vasomotor and other postmenopausal symptoms and should, therefore, improve the quality of life for patients with epithelial ovarian cancer.


Lipkowitz S, Kohn EC. To Treat or Not to Treat: The Use of Hormone Replacement Therapy in Patients With Ovarian Cancer. JCO Dec 10, 2015:4127-4128; published online on October 5, 2015.


Content updated 9 December 2015


Print Email


Facebook Follow AMS on Linkedin Follow us on Twitter @amsmenopauseAMS on Instagram